Skip to main content
    New Biomarkers and Therapeutics Show Potential in Still's Disease

    AOSD is a rare complex, sporadic, systemic autoinfla

    Dr. John Cush RheumNow

    3 months 1 week ago
    New Biomarkers and Therapeutics Show Potential in Still's Disease AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis https://t.co/cGBBHsBdK7 https://t.co/a0EwBiTJSu
    Urinary biomarkers precede loss of kidney function for lupus nephritis

    In Abstract 0850, Dr. Andrea Fava from Johns Ho

    Dr. John Cush RheumNow

    3 months 1 week ago
    Urinary biomarkers precede loss of kidney function for lupus nephritis In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation. https://t.co/MJb9F3uEgr https://t.co/oXvNLelE89
    Less (Glucocorticoids) is More in Lupus Nephritis

    Dr. Yuz Yusof talks with Dr. Amir Saxena about abstract 0781 at the

    Dr. John Cush RheumNow

    3 months 1 week ago
    Less (Glucocorticoids) is More in Lupus Nephritis Dr. Yuz Yusof talks with Dr. Amir Saxena about abstract 0781 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/EriaJvBPj9 https://t.co/x5hNIAgBz2
    Difficult toTreat PsA: Mainly Difficult to Define!

    Dr. Aurelie Najm reports on abstract 0777 from the 2023 ACR Converg

    Dr. John Cush RheumNow

    3 months 1 week ago
    Difficult toTreat PsA: Mainly Difficult to Define! Dr. Aurelie Najm reports on abstract 0777 from the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/vXDY47xWfS https://t.co/l5hJFc7blH
    Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology

    The top ACR2023 Plenary abstracts Dr. Dao ( @kdao2

    Dr. John Cush RheumNow

    3 months 1 week ago
    Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology The top ACR2023 Plenary abstracts Dr. Dao ( @kdao2011) found impactful for her practice were... https://t.co/aXut7l7b79 https://t.co/ATO5r5OzGK
    Chronic low back pain is a common complaint that brings patients to the doctor’s attention. Although the majority of low back pain is mechanical in nature, an important minority is inflammatory in nature. Therefore, prompt referral to a rheumatologist is warranted particularly in the presence of other features suggestive of axial spondyloarthritis (axSpA).
    Rheumatology Roundup
    Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
    ACR23 – Day 3 Report

    F2F learning amidst miles of research and many young talented aside wizened establish presente

    Dr. John Cush RheumNow

    3 months 1 week ago
    ACR23 – Day 3 Report F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be. https://t.co/TwmwfEQZdp https://t.co/Yo27c7ig8N
    Watch: Lupus Nephritis Therapy Paradigm Shift

    Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence mee

    Dr. John Cush RheumNow

    3 months 1 week ago
    Watch: Lupus Nephritis Therapy Paradigm Shift Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/poIVX74EnO https://t.co/tWlRlwTfH0
    IV Secukinumab for AxSpa

    The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with ps

    Dr. John Cush RheumNow

    3 months 1 week ago
    IV Secukinumab for AxSpa The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. https://t.co/eDAWevPLkE https://t.co/AlWYGAQP5T
    Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA

    Dr. Robert Chao (Tysons, VA) discusses Abst

    Dr. John Cush RheumNow

    3 months 1 week ago
    Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI
    How early is early in psoriatic arthritis?

    Is there a window of opportunity for treatment in PsA to ensure optimal ou

    Dr. John Cush RheumNow

    3 months 1 week ago
    How early is early in psoriatic arthritis? Is there a window of opportunity for treatment in PsA to ensure optimal outcomes? https://t.co/SHA8Gdm1GD https://t.co/GbFfeB2Euw
    Cancer and TNF inhibitors

    Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for

    Dr. John Cush RheumNow

    3 months 1 week ago
    Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions https://t.co/MzksmSEUjf https://t.co/dxCIHxL1gc